Skip to content
T7T7T7

Drawing based on the label description. No photo yet.

“500 mg peach colored, capsule shaped, biconvex, film coated tablets, debossed 'T7' on one side and plain on other side”

T7 pill

Pill with imprint T7 is orange, capsule, 19 mm and has been identified as Levofloxacin 500 mg. It is used for bronchitis, urinary tract infections (UTIs) and pneumonia. It is supplied by Macleods Pharmaceuticals Limited.

Levofloxacin 500 mg

Imprint
T7
Strength
500 mg
Used for
Bronchitis, urinary tract infections (UTIs) and pneumonia
Color
Orange
Shape
Capsule / oblong
Size
19 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Macleods Pharmaceuticals Limited
Drug class
Antibiotic (fluoroquinolone)
NDC
33342-532, 33342-532-08, 33342-532-31, 33342-532-12, 33342-532-11, 67296-0743, 67296-0743-5, 67296-0743-7, 67296-0743-1

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Levofloxacin pills and guides

What is Levofloxacin used for?

Levofloxacin is used for bronchitis, urinary tract infections (UTIs), pneumonia and skin infections.

Medicine type
Antibiotic (fluoroquinolone)
Official uses from the US prescribing label

Nosocomial Pneumonia

Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae,or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosais a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.

Community-Acquired Pneumonia: 7 to 14 day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae(including multi-drug-resistant Streptococcus pneumoniae[MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila,or Mycoplasma pneumoniae.

MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2 ndgeneration cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

Community-Acquired Pneumonia: 5-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae(excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae,or Chlamydophila pneumoniae.

Complicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes,or Proteus mirabilis.

Uncomplicated Skin and Skin Structure Infections

Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus,or Streptococcus pyogenes.

Chronic Bacterial Prostatitis

Levofloxacin tablets are indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis,or methicillin-susceptible Staphylococcus epidermidis.

Inhalational Anthrax (Post-Exposure)

Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracisin adults and pediatric patients, 6 months of age and older. The effectiveness of levofloxacin tablets is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets have not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk.

Plague

Levofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis( Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older.

Efficacy studies of levofloxacin tablets could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.

Complicated Urinary Tract Infections: 5-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae,or Proteus mirabilis.

Complicated Urinary Tract Infections: 10-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,or Pseudomonas aeruginosa.

Acute Pyelonephritis: 5 or 10-day Treatment Regimen

Levofloxacin tablets are indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.

Uncomplicated Urinary Tract Infections

Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae,or Staphylococcus saprophyticus.

Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin tablets for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options.

Acute Bacterial Exacerbation of Chronic Bronchitis

Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae,or Moraxella catarrhalis.

From the FDA-approved label on DailyMed (published Sep 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows T7 and the other side is plain.
  • It is orange, capsule, 19 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Levofloxacin

Inactive: Crospovidone, Cellulose, Microcrystalline, Magnesium Stearate, Titanium Dioxide, Polysorbate 80, Ferric Oxide Red, Ferric Oxide Yellow, Hypromelloses, Polyethylene Glycol, Unspecified

Also distributed by

Redpharm Drug

Other pills with imprint T 7

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Levofloxacin pills